SNPMiner Trials (Home Page)
Report for SNP rs13266634
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
There are 2 clinical trials
Clinical Trials
1 Nutrigenomics of Zinc Supplementation in Insulin Secretion and Diabetes
The purpose of this study is to evaluate the effect of zinc supplementation on insulin secretion by genotype of SLC30A8.
NCT00981448 Diabetes Dietary Supplement: Zinc acetate MeSH:Diabetes Mellitus
HPO:Diabetes mellitus
Inclusion Criteria: - aged 21-70 years - Amish decent - genotyping of rs13266634 of SLC30A8 gene - previously consented to contact for future studies and future use of DNA Exclusion Criteria: - Subject is a first-degree relative of another subject with the same SLC30A8 genotype - diabetes mellitus (by history, treatment or random BG>200 mg;dl) - gastrointestinal disease causing nausea, vomiting, or diarrhea including inflammatory bowel disease by history.
- rheumatoid arthritis by history - albumin < 3.5 g/dL - hemochromatosis by history - hematocrit <34% - liver disease by history - alanine aminotransferase or aspartate aminotransferase greater than 2.5 times normal - renal failure by history - estimated glomerular filtration rate < 60 mL/min by MDRD equation - use of thiazide diuretic and unwilling to discontinue if deemed safe in the opinion of the treating physician and study physician for 1 week prior to protocol initiation - use of systemic corticosteroid and unwilling to discontinue if deemed safe in the opinion of the treating physician and study physician for 1 week prior to protocol initiation - use of highly-active antiretroviral medications - use of antipsychotic medications - use of quinolone antibiotics - use of tetracycline antibiotic and unwilling to discontinue if deemed safe in the opinion of the treating physician and study physician for 1 week prior to protocol initiation - use of chelation therapy in the past month - unwilling to withdraw from supplements for 1 week prior to the study and throughout study - abnormal thyroid stimulating hormone (TSH) level - serious disease precluding participation - reported pregnancy or positive urine hCG test - cancer diagnosis in past 2 years - breastfeeding - use of denture adhesive Inclusion Criteria: - aged 21-70 years - Amish decent - genotyping of rs13266634 of SLC30A8 gene - previously consented to contact for future studies and future use of DNA Exclusion Criteria: - Subject is a first-degree relative of another subject with the same SLC30A8 genotype - diabetes mellitus (by history, treatment or random BG>200 mg;dl) - gastrointestinal disease causing nausea, vomiting, or diarrhea including inflammatory bowel disease by history.
Primary Outcomes
Measure: Change in acute insulin response from IVGTT. Time: 14 daysSecondary Outcomes
Measure: change in insulin sensitivity Time: 14 daysMeasure: change in disposition index Time: 14 days
Measure: self-report of history of symptoms of anemia or gastrointestinal symptoms during study Time: 14 days
Measure: change in serum zinc Time: 14 days
Measure: change in urinary zinc Time: 14 days
2 Effect of SLC30A8 rs13266634 Genetic Polymorphism on Zinc Supplementation and Glycemic Control in Egyptian Patients With Type 2 Diabetes Mellitus
Study whether SLC30A8 rs13266634 polymorphism is associated with type 2 diabetes mellitus (T2DM) susceptibility in Egyptian patients and study effect of Zn supplementation on glycemic control in patients with type 2 diabetes
NCT03112382 Diabetes Mellitus, Type II Drug: zinc supplement plus vitamin A and E Drug: vitamin A and E MeSH:Diabetes Mellitus Diabetes Mellitus, Type 2
HPO:Diabetes mellitus Type II diabetes mellitus
Effect of SLC30A8 rs13266634 Genetic Polymorphism on Zinc Supplementation and Glycemic Control in Egyptian Patients With Type 2 Diabetes Mellitus Study whether SLC30A8 rs13266634 polymorphism is associated with type 2 diabetes mellitus (T2DM) susceptibility in Egyptian patients and study effect of Zn supplementation on glycemic control in patients with type 2 diabetes SLC30A8 rs13266634 polymorphism.
Primary Outcomes
Description: genetic screening of SLC30A8 : solute carrier family 30 member 8
Measure: SLC30A8 rs13266634 polymorphism Time: one yearMeasure: serum zinc Time: at base line
Secondary Outcomes
Measure: change from baseline in fasting and 2hr post prandial blood glucose at three months Time: at base line and after three monthsMeasure: change from baseline in HbA1c at three months Time: base line and three months
Description: lipid profile: total cholesterol, triglyceride, HDL, LDL.
Measure: change from baseline in lipid profile at three months Time: base line and three monthsMeasure: change from baseline in fasting serum insulin at three months Time: baseline and three months
Measure: change from baseline in ALT level at three months Time: baseline and three months
Measure: serum Mg Time: baseline
Measure: creatinine level Time: baseline
Measure: serum Iron Time: baseline
Measure: change from baseline in total serum Calcium at three months Time: baseline and three months